DO NOT ATTEMPT THIS BY YOURSELF WITHOUT THE ADVISE OF AN EXPERT IN THIS PRODUCT. VERY BAD CONSEQUENCES CAN HAPPEN BY IRRESPONSIBLY TRYINT TO USE THIS PRODUCT ON YOUR OWN. DO NOT USE, THIS IS JUST THEORETICAL THINKING.
There is still not enough scientific evidence and feedback, but this chemical could be a huge hope for penile enlargement. Although it has never been mentioned for this purpose, this chemical was first developed by Pfizer under the name of XIAFLEX for the treatment of Dupuytren's contracture, which is a disease in which collagen builds up in the palm of the hand, preventing the fingers from stretching out.
Soon after its release and approval by the FDA, Urologists pointed out the chemical as a hope to treat Peyronies disease. Initially Pfizer advised against this purpose, but today it seems to be a treatment being used.
What is interesting, this chemical is injectable, it acts directly in the location applied, it does not reach the bloodstream. It is composed by two enzymes, and both break down small portions of collagen. Of course in the case of Peyronies disease it is applied in the exact location where curve is, but in the case of penile enlargement, it would have to be applied in multiple areas along the shaft, while wearing an extender for prolonged periods of time.
I believe in my own perception that a routine with this chemical for a determined period of time, can lead to revolutionary increase in length. I also believe that while doing the treatment, supplementation with collagen would be necessary to facilitate the tissue repair process. The constant traction from the extender, would allow a re sharpening of the penis, healing in a permanent larger state.
OPINIONS??
https://en.wikipedia.org/wiki/Collag...m_histolyticum
Collagenase clostridium histolyticum
From Wikipedia, the free encyclopedia
Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of Dupuytren's contracture, a condition where the fingers bend towards the palm and cannot be fully straightened, and Peyronie's disease, a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. BioSpecifics Technologies developed the preparation, which is manufactured and marketed by Auxilium Pharmaceuticals as Xiaflex in the US and by Sobi as Xiapex in Europe.
Uses[edit]
In February 2010, the Food and Drug Administration of the United States approved Xiaflex for the treatment of Dupuytren's contracture.[1][2] It is the first approved nonsurgical treatment for this condition.[3] In a case of Dupuytren's contracture, collagen accumulates in the palmar fascia of the hands, so that the fingers cannot be straightened. A similar phenomenon occurs in Peyronie's disease, a contracture of the penis.
In February 2011, the European Commission's Committee for Medicinal Products for Human Use approved the product for the treatment of Dupuytren's contracture in adults with a palpable cord by 'properly trained' doctors.[4]Pfizer was reported to be working with Europe's national medicines regulatory bodies to launch the new treatment, hoping doctors could prescribe the treatment by late 2011.[5]
On November 7, 2012, BioSpecifics announced "BioSpecifics Technologies Corp. : Reports Third Quarter 2012 Financial Results". Auxilium's submission of a License Application to the FDA for XIAFLEX for the potential treatment of Peyronie's disease, an excess of inelastic collagen causing penile curvature deformity. The FDA approved Xiaflex for the treatment of Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval for the treatment of Peyronie’s disease in February 2015, making it the first and only biologic therapy indicated for the treatment of Peyronie's disease.[6] Auxilium has also reported additional trials for potential use of Xiaflex are underway for the treatment of Frozen Shoulder, Cellulite reductions and both Human and Canine Lipoma's.[7]
Side effects[edit]
The most common side effects include lymphadenopathy (swollen lymph nodes), itching, pain, oedema, and bleeding (for example in the form of bruises or ecchymoses). Allergic reactions are seen in less than 1% of patients.[8]
Chemical properties[edit]
The substance is a constant mixture of two collagenases (AUX-I and AUX-II) with known amino acid sequences and a length of about 1000 amino acids each. It is prepared by anaerobic fermentation from a strain of C. histolyticum that has been known since 1950.[9]
Pharmacology[edit]
The enzymes do not reach the bloodstream in significant amounts and are presumed to largely stay at the point of injection[8] until they are broken down by proteases.
The two collagenases act synergistically by cleaving tropocollagen (the 'collagen molecule') at different points. AUX-I attacks the C- and N-termini, AUX-II cleaves amino acid bonds within the molecule. Small collagen fragments are broken down by both enzymes.[9]
Interactions[edit]
No interaction studies have been conducted because the drug does not reach the bloodstream and the liver. It is theorised that drugs interfering with matrix metalloproteinases, such as tetracyclines, anthracyclines, quinolones and anthraquinone derivatives, could reduce the efficacy of the collagenases, but no clinical evidence for such an interaction has been observed.[8]
References[edit]
Categories:
There is still not enough scientific evidence and feedback, but this chemical could be a huge hope for penile enlargement. Although it has never been mentioned for this purpose, this chemical was first developed by Pfizer under the name of XIAFLEX for the treatment of Dupuytren's contracture, which is a disease in which collagen builds up in the palm of the hand, preventing the fingers from stretching out.
Soon after its release and approval by the FDA, Urologists pointed out the chemical as a hope to treat Peyronies disease. Initially Pfizer advised against this purpose, but today it seems to be a treatment being used.
What is interesting, this chemical is injectable, it acts directly in the location applied, it does not reach the bloodstream. It is composed by two enzymes, and both break down small portions of collagen. Of course in the case of Peyronies disease it is applied in the exact location where curve is, but in the case of penile enlargement, it would have to be applied in multiple areas along the shaft, while wearing an extender for prolonged periods of time.
I believe in my own perception that a routine with this chemical for a determined period of time, can lead to revolutionary increase in length. I also believe that while doing the treatment, supplementation with collagen would be necessary to facilitate the tissue repair process. The constant traction from the extender, would allow a re sharpening of the penis, healing in a permanent larger state.
OPINIONS??
https://en.wikipedia.org/wiki/Collag...m_histolyticum
Collagenase clostridium histolyticum
From Wikipedia, the free encyclopedia
|
Intralesional injection |
|
9001-12-1 https://upload.wikimedia.org/wikiped..._check.svg.png |
M09AB02 |
SID 138909 |
DB00048 https://upload.wikimedia.org/wikiped...X_mark.svg.png |
none |
AA4500 |
114 kg/mol (AUX-I), 113 kDa (AUX-II) |
Uses[edit]
In February 2010, the Food and Drug Administration of the United States approved Xiaflex for the treatment of Dupuytren's contracture.[1][2] It is the first approved nonsurgical treatment for this condition.[3] In a case of Dupuytren's contracture, collagen accumulates in the palmar fascia of the hands, so that the fingers cannot be straightened. A similar phenomenon occurs in Peyronie's disease, a contracture of the penis.
https://upload.wikimedia.org/wikiped...Dupuytrens.jpg
Collagenase clostridium histolyticuminjection for Dupuytren's contracture. Before, next day, and two weeks after first treatment
Collagenase clostridium histolyticuminjection for Dupuytren's contracture. Before, next day, and two weeks after first treatment
In February 2011, the European Commission's Committee for Medicinal Products for Human Use approved the product for the treatment of Dupuytren's contracture in adults with a palpable cord by 'properly trained' doctors.[4]Pfizer was reported to be working with Europe's national medicines regulatory bodies to launch the new treatment, hoping doctors could prescribe the treatment by late 2011.[5]
On November 7, 2012, BioSpecifics announced "BioSpecifics Technologies Corp. : Reports Third Quarter 2012 Financial Results". Auxilium's submission of a License Application to the FDA for XIAFLEX for the potential treatment of Peyronie's disease, an excess of inelastic collagen causing penile curvature deformity. The FDA approved Xiaflex for the treatment of Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval for the treatment of Peyronie’s disease in February 2015, making it the first and only biologic therapy indicated for the treatment of Peyronie's disease.[6] Auxilium has also reported additional trials for potential use of Xiaflex are underway for the treatment of Frozen Shoulder, Cellulite reductions and both Human and Canine Lipoma's.[7]
Side effects[edit]
The most common side effects include lymphadenopathy (swollen lymph nodes), itching, pain, oedema, and bleeding (for example in the form of bruises or ecchymoses). Allergic reactions are seen in less than 1% of patients.[8]
Chemical properties[edit]
The substance is a constant mixture of two collagenases (AUX-I and AUX-II) with known amino acid sequences and a length of about 1000 amino acids each. It is prepared by anaerobic fermentation from a strain of C. histolyticum that has been known since 1950.[9]
Pharmacology[edit]
The enzymes do not reach the bloodstream in significant amounts and are presumed to largely stay at the point of injection[8] until they are broken down by proteases.
The two collagenases act synergistically by cleaving tropocollagen (the 'collagen molecule') at different points. AUX-I attacks the C- and N-termini, AUX-II cleaves amino acid bonds within the molecule. Small collagen fragments are broken down by both enzymes.[9]
Interactions[edit]
No interaction studies have been conducted because the drug does not reach the bloodstream and the liver. It is theorised that drugs interfering with matrix metalloproteinases, such as tetracyclines, anthracyclines, quinolones and anthraquinone derivatives, could reduce the efficacy of the collagenases, but no clinical evidence for such an interaction has been observed.[8]
References[edit]
- Jump up ^ "FDA Approves Xiaflex for Debilitating Hand Condition". Food and Drug Administration. February 2, 2010. Retrieved March 16, 2010.
- Jump up ^ Pollack, Andrew (March 15, 2010). "Triumph for Drug to Straighten Clenched Fingers". The New York Times. Retrieved March 16, 2010.
- Jump up ^ Pollack, Andrew (March 15, 2010). "Bringing Movement Back to Clenched Hands". The New York Times. Retrieved March 16, 2010.
- Jump up ^ Xiapex: collagenase clostridium histolyticum, European Medicines Agency, Undated.Accessed: 20 March 2011.
- Jump up ^ Xiapex (Collagenase Clostridium Histolyticum) Authorised In The European Union For Dupuytren's Contracture, Medical News Today, Bexhill-on-Sea, East Sussex, 3 March 2011.Accessed: 19 March 2011.
- Jump up ^ Xiapex summary of product characteristics
- Jump up ^ "Xiaflex for the Treatment of Cellulite".
- ^ Jump up to: a b c Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.
- ^ Jump up to: a b A. Klement (9 May 2011). "Dupuytren'sche Kontraktur erstmals medikamentös behandelbar: Xiapex". Österreichische Apothekerzeitung (in German) (10/2011): 8.
Categories:
Comment